title: Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease.
abstract: Alzheimer's disease (AD) is characterized by amyloid beta (A beta) accumulation in the brain and is classified as familial early-onset (FAD) or sporadic late-onset (SAD). Evidences suggest that deficits in the brain expression of insulin degrading enzyme (IDE) and neprilysin (NEP), both proteases involved in amyloid degradation, may promote A beta deposition in SAD. We studied by immunohistochemistry IDE and NEP cortical expression in SAD and FAD samples carrying the E280A presenilin-1 missense mutation. We showed that IDE, a soluble peptidase, is linked with aggregated A beta 40 isoform while NEP, a membrane-bound protease, negatively correlates with amyloid angiopathy and its expression in the senile plaques is independent of aggregated amyloid and restricted to SAD cases. NEP, but not IDE, is over-expressed in dystrophic neurites, both proteases are immunoreactive in activated astrocytes but not in microglia and IDE was the only one detected in astrocytes of white matter from FAD cases. Collectively, our results support the notion that gross conformational changes involved in the modification from "natively folded-active" to "aggregated-inactive" IDE and NEP may be a relevant pathogenic mechanism in SAD.
authors.affiliation: Fundación Instituto Leloir - Instituto de Investigaciones Bioquímicas Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina.
authors.forename: Verónica Berta
authors.initials: VB
authors.lastname: Dorfman
authors.forename: Laura
authors.initials: L
authors.lastname: Pasquini
authors.forename: Miguel
authors.initials: M
authors.lastname: Riudavets
authors.forename: Juan José
authors.initials: JJ
authors.lastname: López-Costa
authors.forename: Andrés
authors.initials: A
authors.lastname: Villegas
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Troncoso
authors.forename: Francisco
authors.initials: F
authors.lastname: Lopera
authors.forename: Eduardo Miguel
authors.initials: EM
authors.lastname: Castaño
authors.forename: Laura
authors.initials: L
authors.lastname: Morelli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000201:enzymology* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D001253:Astrocytes / Q000201:enzymology; D016657:Cerebral Amyloid Angiopathy / Q000201:enzymology; D002540:Cerebral Cortex / Q000201:enzymology* / Q000473:pathology; D005260:Female; D006801:Humans; D007339:Insulysin / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D017628:Microglia / Q000201:enzymology; D008875:Middle Aged; D015260:Neprilysin / Q000737:chemistry / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism*; D058225:Plaque, Amyloid / Q000201:enzymology; D053764:Presenilin-1 / Q000032:analysis / Q000235:genetics; D011487:Protein Conformation
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D053764:Presenilin-1; C078592:amyloid beta-protein (1-40); D015260:Neprilysin; D007339:Insulysin